Citations

Clear

13603 citation(s) found for "_, _".

NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2025
Wood, Douglas E. , Kazerooni, Ella A. , Argento, Christine, Baines, Jonathan, Boer, Brian, Donington, Jessica , Eapen, Georgie A. , Ferguson, J. Scott , Hou, Lifang , Klippenstein, Donald, Kolansky, Ana S., Leung, Ann N. , Mazzone, Peter J. , Merritt, Robert E. , Norris, Kim, Onaitis, Mark W. , Pipavath, Sudhakar, Puri, Varun , Raz, Dan J. , Reddy, Chakravarthy, Reid, Mary E. , Sandler, Kim L. , Sears, Catherine R. , Tanoue, Lynn, Thacker, Amber L., Tong, Betty C. , Wei, Benjamin , McCullough, Beth, Ramakrishnan, Swathi , Hou, Lifang , Leung, Ann , Aberle, Denise R. , Brown, Lisa Marie , Kumar, Rohit , Leard, Lorriana E. , Sands, Jacob , Schabath, Matthew B. , Studts, Jamie L. , Thacker, Amber L., Travis, William D. , Westover, Kenneth D.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 15, 2025 | Volume: 23 | Issue: 1 | Pages: No page available

10.6004/jnccn.2025.0002 | PMID 39819601 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Lung Cancer Screening provide criteria for selecting individuals for screening and offer recommendations for evaluating and managing lung nodules detected during initial and subsequent annual screening. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Lung Cancer Screening.
Abstract 273: Evaluating Clinical Outcomes and Cost‐Effectiveness of Robotic Carotid Artery Stenting: A Multi‐Center, Propensity Score Matched Study
Patel, Sheel , Scott, Kyle, Abbas, Richat, Fuleihan, Antony A. , Sivaganesan, Ahilan, Tjoumakaris, Stavropoula , Gooch, M, Rossenwasser, Robert H., Srinivasan, Visish M. , Burkhardt, Jan‐Karl , Jabbour, Pascal , Roy, J., Musmar, Basel , Sarikonda, Advith , Scott, K., Abbas, R., Jabbour, Pascal

Mayo Clinic

Stroke: Vascular and Interventional Neurology | January 15, 2025 | Volume: 4 | Issue: S1 | Pages: No page available

10.1161/svin.04.suppl_1.273 Get It

Objective Preclinical studies suggest that robotic carotid artery stenting (CAS) could be superior to manual CAS. However, very limited comparative data exists comparing robotic and manual CAS patients. In addition, no data exists comparing the costs of manual and robotic CAS. Methods All robotic CAS cases at 2 academic neurosurgery centers were retrospectively reviewed and 1:1 propensity matched with manual CAS cases. Personnel costs, supply costs, and total procedure costs were collected in collaboration with hospital administration using time‐driven activity‐based cost‐analysis (TDABC). Results 24 robotic CAS cases were performed between 2019 and 2023. Co‐morbidities and baseline procedural characteristics were well‐matched between robotic and manual cases. Unplanned manual conversion was observed in only one robotic case (4.2%). Robotic CAS complications and outcomes were comparable to manual. Robotic CAS was associated with a significantly increased fluoroscopy time (29.0 vs. 19.2 min.; p<0.001). Robotic procedure time (88.9±18.2 min.) was significantly (p=0.003) higher than manual (68.72±22.4 min.). Health professional costs ($1,589.71±176.92, $1,375.99±233.39, p<0.005), supply cost ($3,918.25±421.20, $2,152.74±1,030.26, p<0.001) and total procedure costs ($5,306.11±608.95, $3,437.56±1,165.67, p<0.001) were greater for robotic CAS. Conclusions With a low rate of technical failure and post‐operative complications, we show robotic carotid artery stenting is safe and feasible in the first multi‐center and largest sample to date. In addition, robotic CAS achieves comparable clinical outcomes. Robotic CAS was associated with increased fluoroscopy time, but fluoroscopy time decreased as operators gained familiarity with the CorPath GRX. Robotic CAS was associated with a greater procedural cost, which was driven by greater personnel and supply costs. Our findings highlight the need for further studies to optimize robotic CAS and reduce its associated costs.
Socioeconomic, racial-ethnic, household, and infrastructural disparities of hematologic cancer outcomes in the United States
Fei‐Zhang, David J. , Wu, Erik , Stanisic, Alexander , Hou, Lifang , Platanias, Leonidas C. , Ansell, Stephen M., Lewis‐Thames, Marquita W. , Badawy, Sherif M. , Stanisic, Alexander V , Paludo, Jonas , Badawy, Sherif M , Hou, Lifang , Fei-Zhang, David , Ansell, Stephen M. , Paludo, Jonas

Mayo Clinic

Blood Advances | January 14, 2025 | Volume: 9 | Issue: 6 | Pages: 1463-1471

10.1182/bloodadvances.2024013956 | PMID 39808792 Get It

Abstract Although social determinants of health (SDoH) investigations have shown limited analyses of socioeconomic and race-ethnic status on certain hematologic malignancies, the impact of factors beyond those across a fuller scope of hematologic cancers remains unknown. The Social Vulnerability Index (SVI), a tool for assessing varied US census–derived sociodemographic factors, allows for the specific quantification of SDoH in dynamic, regional contexts for their associations with hematologic malignancy inequities. To assess the summative influence of varied SDoH factors on hematologic malignancy outcomes and discern which SDoH factors contributed the largest associations toward disparities, 796 005 adults with hematologic malignancies between 1975 to 2017 were identified for this retrospective cohort study. Vulnerability in 15 SDoH factors was measured using composite and subcategory SVI scores geographically matched to patients. Regressions between SVI factors and follow-up time after diagnosis and survival period were performed. Increasing overall SVI correlated with significantly decreased surveillance period in 11 of 14 hematologic malignancies, with decreases upward of 33.4% (39.0-26.0 months for acute lymphocytic leukemia). Increasing SVI significantly associated with decreased survival period across 11 of 14 hematologic malignancies, with decreases upward of 47.2% (89.5-47.3 months for Hodgkin lymphoma). Socioeconomic status and housing and transportation vulnerabilities showed the largest magnitude of contributions, followed by minority language and household composition. Significant decreases in hematologic malignancy prognosis associate with increasing overall SDoH vulnerability in varied sociodemographic contexts in the United States. Furthermore, there are quantifiable differences in which types of SDoH contribute more to trends per malignancy type. These findings demonstrate specific SDoH targets for further research and policy initiatives to combat hematologic malignancy disparity more effectively.
Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study
Naing, Aung , Javle, Milind , Bajor, David L. , Shields, Anthony F. , Chawla, Sant P. , Safran, H., Powderly, John D. , D’Amato, Gina Z. , Meyer, Christian F. , Tang, Xiongwen , Yao, Sheng , Keegan, Patricia , Keegan, Patricia , Mahipal, Amit , Wang, Judy , Bauer, Todd Michael , Elias, Anthony , Davis, Elizabeth J.

Mayo Clinic

Journal of Immunotherapy and Precision Oncology | January 14, 2025 | Volume: 8 | Issue: 1 | Pages: 71-81

10.36401/jipo-24-8 | PMID 39816916 Get It

Introduction This was the first phase 1 study conducted in the United States. It consisted of dose-escalation (part A) and multiple indication-specific cohort expansion (part B), investigating the safety and preliminary efficacy of toripalimab (anti–programmed cell death-1 inhibitor) in patients with advanced malignancies. Methods Patients with advanced malignancies that progressed after treatment with at least one prior line of standard systemic therapy, including the patients with advanced/recurrent cholangiocarcinoma (CCA), received toripalimab 240 mg every 3 weeks in part B. The primary endpoint was safety assessment. Efficacy endpoints included objective response rate (ORR), disease control rate (DCR), duration of response (DoR), progression-free survival (PFS) as assessed by the investigators according to Response Evaluation Criteria in Solid Tumors (version 1.1) and overall survival (OS). Results In part B, 166 patients, including the 42 patients with CCA, were enrolled and received toripalimab. Among the 166 patients, treatment-emergent adverse events (TEAEs) of any grade occurred in 158 (95.2%) patients, and 97 (58.4%) patients experienced TEAEs of Grade 3 or greater. The most common TEAE was fatigue (42.2%). Seven (4.2%) patients experienced TEAEs with a fatal outcome, none of which were identified by investigators as related to toripalimab. Investigator-assessed immune-related adverse events (irAE) of Grade 3 or higher occurred in 7 (4.2%) patients. In the CCA cohort, with the median follow-up of 4.4 months, the ORR and DCR were 4.8% (95% CI: 0.58, 16.16) and 40.5% (95% CI: 25.63, 56.72), respectively; median DoR was 7.8 (range 4.4+ to 7.8) months; median PFS was 2.1 (95% CI: 1.91, 3.88) months; median OS was not estimable. Conclusions Toripalimab had manageable side effects in patients with refractory cholangiocarcinoma and exhibited preliminary evidence of anti-tumor activity. However, further information regarding biomarkers is needed. ClinicalTrials.gov ID: NCT03474640
Traumatic Vertebral Artery Injury After Subaxial Cervical Spine Injuries: Incidence, Risk Factors, and Long-Term Outcomes: A Population-Based Cohort Study
El-Hajj, Victor Gabriel , Habashy, Karl J. , Cewe, Paulina , Atallah, Elias , Singh, Aman , Fletcher‐Sandersjöö, Alexander , Bydon, Mohamad , Fagerlund, Michael, Jabbour, Pascal , Elmi‐Terander, Adrian , Elmi-Terander, Adrian , El-Hajj, Victor Gabriel , Jabbour, Pascal , Gerdhem, Paul , Edström, Erik

Mayo Clinic

Neurosurgery | January 14, 2025 | Volume: 96 | Issue: 4 | Pages: 881-891

10.1227/neu.0000000000003173 | PMID 39808539 Get It

BACKGROUND AND OBJECTIVES: Vertebral artery injury (VAI) because of traumatic subaxial cervical spine injury is a rare but potentially devastating condition as it could lead to stroke. The aim of this study was to examine the incidence, risk factors, outcomes, and radiographic predictors of VAI in patients surgically treated for subaxial cervical spine injuries at a tertiary care trauma center. METHODS: This is a retrospective population-based cohort study, including all patients surgically treated for traumatic subaxial cervical spine injuries at the study center between 2006 and 2018. Primary outcomes included mortality and morbidity after the injury. Propensity score matching, survival, univariable, and multivariable analyses were used to study the outcomes of interest. RESULTS: Traumatic VAI primarily occurred after high-energy traumas such as motor vehicle accidents and falls from heights. The median age was 64.4 years (47.4-69.1), and 69% were male. In the cohort of patients with subaxial cervical injury, 54% had a spinal cord injury (SCI). In the subgroup with VAI, the frequency of SCI was 66% and a concomitant SCI and VAI were associated with a more severe American Spinal Cord Injury Association Impairment Scale grade ( P = .015). However, after accounting for age, sex, and associated injuries, VAI did not affect postoperative complications, short- or long-term outcomes, or mortality rates. Facet joint dislocation was a unique radiographic predictor of VAI (odds ratio 3.8 [CI 1.42-10.7], P = .009). CONCLUSION: The findings suggest that clinical outcomes of patients with traumatic cervical spine injuries were not negatively affected by the presence of a VAI. Several radiographic factors were associated with VAI; however, only facet joint dislocation remained as an independent predictor of this injury.
A Novel Dielectric Fingerprinting Tool for Histopathology Assessment Leveraging AI and RF: A Feasibility Study Using Gastrointestinal Tissues
Gaddam, Sunil , Samaddar, Poulami , Gopalakrishnan, Keerthy, Singh, Mansunderbir, Anvekar, Priyanka , Shivaram, Suganti, Dey, Shuvashis , Roy, Sayan , Mitra, Dipankar , Arunachalam, S P , Dey, Shuvashis , Roy, Sayan , Arunachalam, Shivaram P.

Mayo Clinic

IEEE Journal of Electromagnetics, RF and Microwaves in Medicine and Biology | January 13, 2025 | Volume: 9 | Issue: 3 | Pages: 318-325

10.1109/jerm.2024.3523861 Get It

The dosage of ropeginterferon in polycythaemia vera: Balancing efficacy, safety and pharmacoeconomics across risk categories
Barbui, Tiziano , Tefferi, Ayalew , Vannucchi, Alessandro M. , Vannucchi, Alessandro M

Mayo Clinic

British Journal of Haematology | January 13, 2025 | Volume: 206 | Issue: 3 | Pages: 984-985

10.1111/bjh.19996 | PMID 39800985 Get It

Unmasking Racial, Ethnic, and Socioeconomic Disparities in United States Chordoma Clinical Trials: Systematic Review
Bangash, Ali Haider , Ryvlin, Jessica , Chakravarthy, Vikram , Sullivan, Patricia L. Zadnik, Niu, Tianyi , Galgano, Michael , Shin, John H., Gokaslan, Ziya L. , Fourman, Mitchell S. , Gelfand, Yaroslav , Murthy, Saikiran G. , Yassari, Reza , Galgano, Michael A , Fourman, Mitchell S , De la Garza Ramos, Rafael , Bangash, Ali Haider , Akinduro, Oluwaseun O. , Sullivan, Patricia Zadnik , Ramos, Rafael De la Garza

Mayo Clinic

Cancers | January 13, 2025 | Volume: 17 | Issue: 2 | Pages: 225

10.3390/cancers17020225 | PMID 39858008 Get It

Background: Chordoma is a rare bone cancer with limited treatment options. Clinical trials are crucial for developing effective therapies, but their success depends on including diverse patient populations. The objective of this study was to systematically evaluate the reporting of racial, ethnic, and socioeconomic diversity in United States clinical trials exploring treatment for chordoma. Methods: A literature search was conducted through PubMed/Medline, Cochrane, Epistemonikos, and ClinicalTrials.gov databases for published US chordoma trials up until 19 August 2024. The data collected included trial characteristics and racial and ethnic data, as well as socioeconomic indicators when available. Methodological Index for Non-Randomized Studies (MINORS) and Revised Cochrane Risk-of-Bias Tool for Randomized Trials (RoB2) analyses were adopted to assess the methodological quality. The N-1 Chi-squared (χ2) test was implemented to compare the reported racial and ethnic data with the most recent US Census Bureau data. Results: Five trials involving 111 patients (median age: 63 years; 34% female) were included. Four studies (80%) were single-arm non-randomized studies with one study (25%) having a high methodological quality and three (75%) having a moderate quality based on the MINORS analysis. Most patients (91%, n = 82) were White/Caucasian, representing a proportion which was significantly higher than the reported 75% in the US population (p = 0.0005). Black/African American patients (2%, n = 2) were significantly underrepresented compared to the 14% in the US population (p = 0.0015). Regarding ethnicity, Hispanic/Latino patients (7%, n = 6) were significantly underrepresented compared to the 20% in the US population (p = 0.0021). No measures of socioeconomic status were reported. Conclusions: This systematic review highlighted the need for improved racial and ethnic diversity in chordoma trials and the better reporting of socioeconomic data. The underrepresentation of minority groups may obscure potential disparities in disease incidence, treatment access, and clinical outcomes.
An X-linked long non-coding RNA, PTCHD1-AS, regulates autistic behaviors in humans and in mice
Scherer, Stephen W. , Bradley, Clarrisa A. , Ko, Sangyoon Y. , Ralph, Liam T. , D’Abate, Lia , Lee, Jinyeol, Liu, Tianyi , Wang, Junhui , Tidball, Patrick , Fan, Xiaolian, Howe, Jennifer, Alexandrova, Roumiana, Pellecchia, Giovanna , Casallo, Guillermo, Paton, Tara , Wybenga-Groot, Leanne , Rijke, Jill de , Kadia, Ashish , Salazar, Nelson Bautista , Shum, Carole, Rennie, Olivia , Reuter, Miriam S. , Hoang, Ny , Sarikaya, Ege , Selvanayagam, Thanuja , Rutherford, Annabel, Rivero-Alfaro, Natalia, Marshall, Christian R. , Scala, Marcello , Runke, Cassandra , Kearney, Hutton M. , Francis, David, Plucinicazak, Jill, Iaboni, Alana, Sjaarda, Calvin , Jain, Anjali , Frey, Brendan J., Vorstman, Jacob , Frankland, Paul W. , Scherer, Stephen W , Scala, Marcello , Tian, Meng , Lee, Jinyeol, Liu, Tianyi , Wang, Junhui , Mendes, Marla, Paton, Tara, Engchuan, Worrawat , Thiruvahindrapuram, Bhooma , Trost, Brett , Jin, Fuzi , Díaz-Mejía, J. Javier , MacDonald, Jeffrey R. , Deneault, Éric , Ross, P. Joel, Ellis, James , Georgiou, John , Amini, Aeen Ebrahim, Rivera-Alfaro, Natalia, Marshall, Christian R. , Christodoulou, John , Francis, David I. , Chung, Brian H Y, Pluciniczak, Jill, Wigby, Kristen M. , Nordahl, Christine Wu , Amaral, David Gil , Hudson, Melissa L., Guerin, Andrea, Elsabbagh, Mayada , Landa, Rebecca, Mital, Seema , Lesurf, Robert , Wilson, Michael D. , Ellegood, Jacob , Lerch, Jason P., Lee, Leo J. , Salter, Michael W. , Anagnostou, Evdokia, Collingridge, Graham L.

Mayo Clinic

No container title available | January 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5619348/v1 Get It

Abstract There are ~100 genes or copy number variants (CNVs) used in genetic testing for Autism Spectrum Disorder (ASD, or autism). These genes are protein-coding, and the associated phenotypes often extend beyond socio-behavioral traits seen in autism including cognitive/medical complexities, epilepsy, and ADHD. Here, we characterize 27 males with ASD through whole genome sequencing (WGS), delineating X-chromosome microdeletions that implicate the long non-coding RNA (lncRNA) PTCHD1-AS as an ASD-susceptibility gene (OR=2.56, p=0.01). Two Ptchd1-as knockout (KO) murine models, created by removing the evolutionarily conserved exon-3, show ASD-like features in males, increasing repetitive behaviors and impairing typical social behavior and communication without overt cognitive comorbidities or ADHD-like behaviors. Hippocampus-dependent synaptic function, complex learning, and locomotor activity are unaffected in KO mice. Native nuclear-enriched mouse Ptchd1-as showed sustained expression from post-natal day-7 onward in the dorsal striatum, a predominantly GABAergic brain region implicated in ASD. Multi-omics revealed transcriptomic alterations in striatal oligodendrocyte, astrocyte and neurons impacting myelination and plasticity pathways. Disrupting Ptchd1-as led to reductions in conventional Protein Kinase-C, altered Src and GSK3α/β phosphorylation, and an enhancement of synaptic plasticity (long-term potentiation and long-term depression). Together, these findings implicate striatal molecular and circuit level dysregulation via Ptchd1-as in ASD etiology.
Handwriting Anomalies and Learning Disabilities through Recurrent Neural Networks and Geometric Pattern Analysis
Edralin, Sabrina , Simasiku, Akebu, Malliarou, Dimitra, Xu, Clark , Yue, Zongliang , Alevizos, Vasileios , Messinis, Antonis, Papakostas, George A. , Yue, Zongliang , Edralin, Sabrina , Xu, Clark

Mayo Clinic

2024 International Conference on Electrical, Communication and Computer Engineering (ICECCE) | January 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-6

10.1109/icecce63537.2024.10823456 Get It